$27.55 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter

Analysts expect Heron Therapeutics Inc (NASDAQ:HRTX) to report sales of $27.55 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Heron Therapeutics’ earnings. The highest sales estimate is $30.00 million and the lowest is $25.70 million. Heron Therapeutics posted sales of $11.57 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 138.1%. The business is scheduled to report its next quarterly earnings results on Thursday, May 9th.

On average, analysts expect that Heron Therapeutics will report full year sales of $152.43 million for the current year, with estimates ranging from $137.50 million to $166.40 million. For the next fiscal year, analysts anticipate that the business will report sales of $331.88 million, with estimates ranging from $282.00 million to $386.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.17). The company had revenue of $28.84 million during the quarter, compared to the consensus estimate of $28.05 million. Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%.

Several analysts have weighed in on HRTX shares. Zacks Investment Research cut Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 9th. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. Northland Securities reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, March 11th. Finally, ValuEngine lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $51.82.

NASDAQ HRTX traded up $0.70 during trading hours on Monday, reaching $24.40. 1,014,284 shares of the stock traded hands, compared to its average volume of 880,127. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.00 and a beta of 1.57. Heron Therapeutics has a 1 year low of $21.25 and a 1 year high of $42.90.

Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Heron Therapeutics by 24.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares during the last quarter. Jefferies Group LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $202,000. Verition Fund Management LLC purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $208,000. Stephens Inc. AR purchased a new stake in shares of Heron Therapeutics in the 4th quarter valued at approximately $208,000. Finally, Pacer Advisors Inc. purchased a new stake in shares of Heron Therapeutics in the 3rd quarter valued at approximately $223,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.